Taysha grants ~5.3M options and RSUs to top executives; adopts 4M-share inducement plan

Taysha Gene Therapies, Inc.

CEO Sean Nolan receives 1,184,688 options and 1,184,688 RSUs (total ~2.37M shares).
President & Head of R&D Sukumar Nagendran receives 863,617 options and 863,617 RSUs.
CFO Kamran Alam receives 590,413 options and 590,413 RSUs.
Options vest 25% at 1 year, then monthly over 3 years; RSUs vest equally over 4 years.
Board adopted 2023 Inducement Plan reserving 4M shares for new-hire grants under Nasdaq Rule 5635(c)(4).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.